biostudies-literatureMusisi EBundesministerium für Bildung und ForschungEuropean & Developing Countries Clinical Trials Partnership (EDCTP)Medical Research Councile913-e922https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617392biostudies-literatureUnknown4(11)<h4>Background</h4>Respiratory tract microbiota has been described as the gatekeeper for respiratory health. We aimed to assess the impact of standard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes.<h4>Methods</h4>In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regimens versus standard-of-care who were part of the HIGHRIF study 2 (NCT00760149) and PanACEA MAMS-TB (NCT01785186) clinical trials across a 3-month treatment follow-up period. Samples were from participants in Mbeya, Kilimanjaro, Bagamoyo, and Dar es Salaam, Tanzania. Experimental regimens were composed of different combinations of rifampicin (R), isoniazid (H), pyraziThe Lancet. MicrobeEffect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.PMC7617392IP.2007·32011·013MC_UU_00004/04MC_UU_12023/27IP.2007·32011·01101KA0901Kibiki GSAdegbite BRReither KHoelscher MSanne ISabiiti WNunn AJAdegnika AAMassango IBrake LTSam NBoeree MGrobusch MPTwabi HHSloan DRassool MManyama CHunt RPanACEA consortiumJani IDiacon ADawson RNliwasa MHoffmann LMusisi Ede Jager VMbeya BLutchmun WSabi ILiyoyo ANarunsky KMpagama SKhosa CMtafya BDemel PGSemvua HMhimbira FHoneyborne INorena IEldirdiri SGong XSsengooba WMangu CJugheli LMmbaga BTKelly ADreisbach JNtinginya NEJoloba MGillespie SGillespie SHKirenga BMcHugh TDHeinrich NAarnoutse RWyness AMsefula CLDombay ESasamalo MSvensson EMukoka MFriedrich SWildner LMPhillips PPJMinja LTAzam KfalseEffect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.<h4>Background</h4>Respiratory tract microbiota has been described as the gatekeeper for respiratory health. We aimed to assess the impact of standard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes.<h4>Methods</h4>In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regimens versus standard-of-care who were part of the HIGHRIF study 2 (NCT00760149) and PanACEA MAMS-TB (NCT01785186) clinical trials across a 3-month treatment follow-up period. Samples were from participants in Mbeya, Kilimanjaro, Bagamoyo, and Dar es Salaam, Tanzania. Experimental regimens were composed of different combinations of rifampicin (R), isoniazid (H), pyrazi2023-01-01T00:00:00Z2023 Nov2026-06-01T19:21:39.963Z2025-04-06T22:25:40.71ZS-EPMC76173923783257110.1016/S2666-5247(23)00191-X